science
PhRMA CEO Steve Ubl to Step Down at End of Year After Over a Decade in Role
Steve Ubl, chief executive of the Pharmaceutical Research and Manufacturers of America (PhRMA), will step down at the end of the year. He has led the trade group representing brand-name drug makers for more than a decade. The announcement comes amid ongoing discussions on drug pricing and industry regulations.
ST
Substrate placeholder — needs reviewAudio version
Tap play to generate a narrated version.
Steve Ubl, the chief executive of the Pharmaceutical Research and Manufacturers of America (PhRMA), announced plans to step down from his position at the end of the year. PhRMA serves as the primary trade association for brand-name pharmaceutical companies in the United States. Ubl has held the role for more than a decade, overseeing advocacy efforts on behalf of the industry's interests.
During Ubl's tenure, PhRMA has engaged in key policy debates, including drug pricing reforms and access to innovative medicines. The organization represents major drug manufacturers and focuses on issues such as research and development funding, intellectual property protections, and regulatory frameworks.
Ubl's leadership has coincided with significant legislative actions, such as the Inflation Reduction Act, which introduced new mechanisms for Medicare drug price negotiations.
Leadership PhRMA, founded in 1958, advocates for policies that support biopharmaceutical innovation.
Under Ubl, who assumed the CEO position in 2015, the group navigated challenges including public scrutiny over prescription drug costs and the opioid crisis. Ubl previously served in various roles within the association and the broader healthcare sector. U.S.
government and stakeholders. PhRMA has been involved in lobbying efforts to influence legislation on drug affordability and patent reforms. Ubl's departure will require the board to initiate a search for a successor to continue these activities.
in the healthcare sector, including drug makers, policymakers, and patient advocacy groups, may monitor the leadership transition closely.
The new CEO will inherit ongoing priorities such as responding to federal drug pricing policies and advancing clinical research initiatives. PhRMA has not yet named an interim leader or detailed the timeline for selecting a replacement. Ubl's exit marks the end of a significant era for PhRMA, during which the organization adapted to evolving political and economic landscapes.
